TIRZEPATIDE/GLYCINE 60mg (30MG/0.5MG/ML) - 2mL Vial

Tirzepatide / Glycine 30 mg / 0.5 mg per mL – 2 mL Vial (Total 60 mg Tirzepatide) is a compounded injectable formulation designed for research and clinical interest in metabolic regulation, weight management, and glycemic control. Tirzepatide 30 mg/mL – Tirzepatide is a dual GLP-1 and GIP receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety. These combined effects contribute to significant reductions in blood glucose and body weight. A 2 mL vial provides a total of 60 mg of tirzepatide. It is FDA-approved under Mounjaro for type 2 diabetes. Glycine 0.5 mg/mL – Glycine is an amino acid involved in protein synthesis, neurotransmission, and metabolic pathways. It may support insulin sensitivity, reduce oxidative stress, and contribute to overall metabolic balance. The vial contains a total of 1 mg of glycine. This sterile solution is intended for subcutaneous injection in controlled clinical or investigational settings. Tirzepatide has demonstrated strong efficacy in improving glycemic control and promoting substantial weight loss in clinical trials. Clinical outcomes and metabolic effects of tirzepatide: https://pubmed.ncbi.nlm.nih.gov/33657290/ Mechanism of GLP-1/GIP receptor agonists: https://pubmed.ncbi.nlm.nih.gov/34534432/